Drug Eluting Stent Market Intelligence Report Covers Trends, Segments And Regional Growth

The drug eluting stent market is poised for significant growth as advancements in cardiovascular treatments continue to evolve. With an aging global population and increasing demand for less invasive procedures, this sector is witnessing heightened interest from healthcare providers and patients alike. Let's delve into the current market size, key players, emerging trends, and how the industry is segmented for a clearer understanding of its trajectory.

Projected Market Size and Growth Outlook for the Drug Eluting Stent Market
The drug eluting stent market is projected to expand substantially, reaching a value of $11.7 billion by 2030. This represents a compound annual growth rate (CAGR) of 6.9% during the forecast period. Several factors contribute to this growth, including a rise in the elderly population, heightened demand for minimally invasive cardiac procedures, increasing awareness around advanced stent technologies, the expansion of specialty cardiac clinics, and growing healthcare spending on cardiovascular care. Key market trends that will influence growth include the increased use of biodegradable polymer stents, a shift toward polymer-free drug-eluting stents, greater application in complex coronary interventions, an emphasis on long-term prevention of restenosis, and stronger demand for stents with controlled drug release mechanisms.

Download a free sample of the drug eluting stent market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players in the Drug Eluting Stent Market
The competitive landscape of the drug eluting stent market is shaped by several prominent companies including Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, and Elixir Medical Corporation.

In a notable development, October 2023 saw Cordis, based in the US and specializing in interventional vascular devices, acquire MedAlliance for an undisclosed sum. This acquisition is intended to boost Cordis' cardiovascular innovation portfolio and enhance its offerings in coronary and peripheral vascular markets. MedAlliance, headquartered in Switzerland, is recognized for manufacturing and distributing drug-eluting stents.

View the full drug eluting stent market report:
https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Innovations and Trends Guiding the Drug Eluting Stent Industry
Manufacturers in the drug eluting stent field are prioritizing the creation of advanced products designed to improve ease of use and patient outcomes. A growing focus is on low-profile, highly flexible stents that can navigate challenging coronary anatomies more effectively. These stents feature reduced crossing profiles and enhanced flexibility, facilitating treatment of narrow, tortuous, or calcified arteries while continuing to deliver drugs effectively to prevent restenosis.

For example, Abbott Laboratories introduced the XIENCE Sierra Everolimus Eluting Coronary Stent System in India in May 2024. This stent system boasts a pioneering design with best-in-class deliverability, significantly lowering crossing force compared to competitors. It incorporates a thinner balloon and a refined MULTI LINK structure to enhance flexibility, while maintaining high longitudinal strength for scaffold stability and resistance to deformation. Additionally, it supports a broad expansion range, allowing precise treatment of vessels with varying diameters along the lesion, enabling cardiologists to manage complex and difficult-to-reach lesions with greater safety and accuracy.

Defining the Scope of the Drug Eluting Stent Market Segments
The drug eluting stent market is segmented into several categories to provide detailed insights:

1) Product Type: Polymer-Based and Polymer-Free stents
2) Drug Type: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and other drugs
3) Scaffold Material: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, and other scaffold materials
4) Application Areas: Coronary Diseases and Peripheral Vascular Diseases
5) End-User Groups: Hospitals and Specialty Clinics

Further sub-segmentation includes:
- Polymer-Based Stents: Durable Polymer Drug-Eluting Stents and Biodegradable Polymer Drug-Eluting Stents
- Polymer-Free Stents: Bare-Metal Stents with Drug Coating and other Polymer-Free Drug-Eluting Stents

This detailed classification allows for a comprehensive understanding of market dynamics, ensuring stakeholders can identify precise growth opportunities within the drug eluting stent industry.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.